SAA3 Inhibitors
Chemical inhibitors of Serum Amyloid A3 (SAA3) act primarily through the inhibition of cyclooxygenases (COX), which are key enzymes in the synthesis of prostaglandins involved in inflammatory processes. Acetylsalicylic Acid, a well-known COX inhibitor, directly impedes the enzyme's function, leading to a decrease in prostaglandin production. This reduction is significant as prostaglandins are essential mediators in inflammation, and their diminished presence translates to a reduced functional activity of SAA3. Similarly, Indomethacin, Ibuprofen, Naproxen, and Diclofenac share this mechanism of action, each binding to COX enzymes and thereby curtailing the synthesis of prostaglandins. The outcome of this inhibition is a decrease in the functional activation of SAA3, as the inflammatory signal that it is part of becomes less pronounced.
Celecoxib and Rofecoxib, on the other hand, offer a more targeted approach by selectively inhibiting COX-2, an isoform of the cyclooxygenase enzymes which is particularly associated with inflammatory responses. By focusing on COX-2, these inhibitors effectively reduce the production of prostaglandins in inflamed tissues, which in turn limits the activity of SAA3 within these areas. Other inhibitors such as Sulindac, Ketorolac, and Piroxicam also suppress COX enzyme activity, thereby diminishing prostaglandin synthesis and the subsequent activity of SAA3. Meloxicam and Etodolac further contribute to this inhibitory landscape by selectively blocking COX-2, ensuring a reduction in prostaglandin production, and consequently, the functional activity of SAA3 is decreased. Collectively, these chemical inhibitors modulate the inflammatory pathway by dampening the synthesis of key molecules that regulate the function of SAA3.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $41.00 | 4 | |
Acetylsalicylic Acid, through its ability to inhibit cyclooxygenases (COX), leads to a decrease in prostaglandins which are involved in the inflammatory response where SAA3 plays a role. Inhibiting these mediators can reduce the functional activity of SAA3 in the inflammation process. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
Indomethacin acts as an inhibitor of COX, which are enzymes involved in the inflammatory process that SAA3 is associated with. By inhibiting COX, Indomethacin reduces the production of prostaglandins, thus functionally inhibiting the activity of SAA3. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $52.00 $86.00 | 6 | |
Ibuprofen inhibits COX enzymes, which in turn decreases the synthesis of prostaglandins, key mediators in inflammation that can regulate the function of SAA3. By reducing these mediators, Ibuprofen can functionally inhibit the role of SAA3 in inflammation. | ||||||
Naproxen | 22204-53-1 | sc-200506 sc-200506A | 1 g 5 g | $24.00 $40.00 | ||
Naproxen, a COX inhibitor, decreases the level of prostaglandins, molecules that are implicated in the inflammatory pathway where SAA3 is active. Decreased prostaglandins mean reduced functional activity of SAA3 in this context. | ||||||
Vioxx | 162011-90-7 | sc-208486 | 100 mg | $190.00 | 3 | |
Rofecoxib is a selective COX-2 inhibitor, reducing prostaglandin synthesis in the inflammatory pathway that includes SAA3. The reduction in prostaglandins functionally inhibits the activation and action of SAA3 in inflammation. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $31.00 $84.00 $147.00 | 3 | |
Sulindac, through its metabolites, inhibits COX, which reduces prostaglandin production and could thereby inhibit the function of SAA3 within the inflammatory response where it is active. | ||||||
Diclofenac Sodium | 15307-79-6 | sc-202136 sc-202136A | 5 g 25 g | $40.00 $125.00 | 4 | |
Diclofenac acts as a COX inhibitor, which lowers prostaglandin synthesis. This action can functionally inhibit the role of SAA3 in the inflammation pathway by reducing the activity of key inflammatory mediators. | ||||||
Piroxicam | 36322-90-4 | sc-200576 sc-200576A | 1 g 5 g | $107.00 $369.00 | 2 | |
Piroxicam inhibits COX, ultimately leading to decreased prostaglandin production. Reduced prostaglandin levels can functionally inhibit the role of SAA3 in the inflammation pathway. | ||||||
Meloxicam | 71125-38-7 | sc-200626 sc-200626A sc-200626B | 20 mg 100 mg 500 mg | $35.00 $92.00 $153.00 | 3 | |
Meloxicam is a COX-2 inhibitor that reduces prostaglandin production, decreasing the inflammatory signaling that involves SAA3. By doing so, Meloxicam can functionally inhibit the activity of SAA3 in the inflammatory process. | ||||||
Etodolac | 41340-25-4 | sc-204747 sc-204747A | 100 mg 250 mg | $87.00 $128.00 | 1 | |
Etodolac selectively inhibits COX-2, which plays a role in prostaglandin synthesis within the inflammation pathway. By inhibiting COX-2, Etodolac can limit prostaglandin production, thereby functionally inhibiting SAA3's role in inflammation. | ||||||